Nanjing Vazyme Biotech Co., Ltd (NANJING VAZYME BIOTECH CO LTD) Aktie

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. The company was founded in 2012 and is headquartered in Nanjing, China.